Stockpolly
Search
Delisting risk
PULM · NASDAQ · Biotechnology

Pulmatrix (PULM)

Dry-powder inhalation technology and clinical assets awaiting licensing or monetization.

$1.47
At close−0.05 (−3.61%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue226200000000
Cost of revenue444310000000
Gross profit−2−12−100000000
212522221111
Research & development444310000000
212222221111
General & administrative212222221111
Other expenses−4−4−40−10000000
Operating income−4−21−6−3−2−2−2−1−1−1−1
000000000000
Interest income000000000000
Other non-operating income000−300000000
Income before tax−4−21−6−3−2−2−2−1−1−1−1
Net income from continuing operations−4−21−6−3−2−2−2−1−1−1−1
Net income−4−21−6−3−2−2−2−1−1−1−1
EPS, basic−$1.03−$0.57$0.23−$1.59−$0.71−$0.54−$0.49−$0.42−$0.24−$0.25−$0.32−$0.29
EPS, diluted−$1.03−$0.57$0.23−$1.59−$0.71−$0.54−$0.49−$0.42−$0.24−$0.25−$0.32−$0.29
Weighted average shares, basic444444444444
Weighted average shares, diluted444444444444
EBITDA−4−21−3−3−2−2−2−1−1−1−1
Depreciation & amortization000000000000
EBIT−4−21−3−3−2−2−2−1−1−1−1